logo

For the Inventor, By the Inventor

Ann Arbor, MI, United States of America

John G Topliss

This inventor holds 17 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Warner-Lambert Company, Schering Corporation, Shering Corporation. Active years: 1976-1996.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John G Topliss. Retrieved from https://idiyas.com/inventor/john-g-topliss

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17

% Patents Active = 100.0

Average Co-Inventor Count = 2.4

ph-index = 8

Forward Citations = 289(Granted Patents)


Location History:

  • West Caldwell, NJ (US) (1976 - 1982)
  • Ann Arbor, MI (US) (1984 - 1996)

Company Filing History:

goldMedal10 out of 2,538 
 
Warner-Lambert Company
 patents
silverMedal6 out of 1,829 
 
Schering Corporation
 patents
bronzeMedal1 out of 2 
 
Shering Corporation
 patents

Years Active: 1976-1996

Loading Chart...
Areas of Expertise:
Endothelin Antagonists
Cyclic Amino Acids
Angiotensin II Antagonist
Antiandrogenic Agents
Pharmaceutical Preparations
Cardiotonic Compounds
Oxadiazinone Compounds
Hirsutism Treatment
Peptidyl Derivatives
Saturated Cycloalkyl Amides
17 patents (USPTO):Explore Patents
1. 5550110 - Endothelin Antagonists II (1996-08-27),
2. 5449778 - Cyclic amino acids and derivatives thereof (1995-09-12),
3. 5380925 - Cyclic amino acids and derivatives thereof (1995-01-10),
4. 5276048 - 4-(1H-pyrrol-1-yl)imidazoles with angiotensin II antagonist activity (1994-01-04),
5. 5264577 - Cyclic amino acids and derivatives thereof (1993-11-23),
6. 5210211 - 4-(1H-pyrrol-1-yl) imidazoles with angiotension II antagonist activity (1993-05-11),
7. 5198548 - Process for the preparation of D(-) and L(+)-3,3-diphenylalanine and (1993-03-30),
8. 4758585 - Saturated cycloalkyl (B) pyrrol-1 (2H)- acetic acid amides and (1988-07-19),
9. 4621097 - Saturated cycloalkyl[c] pyrrole-2(1H)-acetic acid amides and derivatives (1986-11-04),
10. 4508718 - Cardiotonic and antihypertensive oxadiazinone compounds (1985-04-02),
11. 4474813 - Pharmaceutical preparations comprising flutamide (1984-10-02),
12. 4329364 - Antiandrogenic agents and methods for the treatment of androgen (1982-05-11),
13. 4169141 - 1-Peptidyl derivatives of di-O-aminoglycosyl-1,3-diaminocyclitol (1979-09-25),
14. 4161540 - Antiandrogenic agents and methods for the treatment of androgen (1979-07-17),
15. 4144270 - Substituted anilides as anti-androgens (1979-03-13),

Title: The Innovative Contributions of John G. Topliss

Introduction

John G. Topliss, an esteemed inventor based in Ann Arbor, MI, has made significant strides in the field of pharmaceuticals through his groundbreaking work. With a portfolio of 17 patents, Topliss has dedicated his career to developing novel compounds and methods that address various critical health issues.

Latest Patents

Among his most recent contributions are his patents for "Endothelin Antagonists II," which describe innovative antagonists of endothelin. These compounds and their pharmaceutical compositions are designed to treat various conditions, including elevated endothelin levels, chronic renal failure, hypertension, myocardial infarction, and several other serious health challenges like stroke and asthma. Additionally, he has developed patents concerning "Cyclic Amino Acids and Derivatives Thereof," which detail a process for preparing biologically active peptides and involve the resolution of D and L enantiomers from racemic cyclic amino acids using unique methods.

Career Highlights

Throughout his career, John G. Topliss has collaborated with prestigious organizations, including Warner-Lambert Company and Schering Corporation. His work has significantly contributed to advancements in pharmaceutical research and development, allowing for improved treatment options for various medical conditions.

Collaborations

Topliss has worked alongside notable colleagues such as Rudolph O. Neri and Vladimir Genukh Beylin. These collaborations have facilitated the sharing of knowledge and expertise, further driving innovation in the pharmaceuticals field.

Conclusion

John G. Topliss stands out as a prominent inventor whose contributions to science and medicine are evident through his extensive patent portfolio. His work not only demonstrates a commitment to improving healthcare but also showcases the importance of innovation in addressing complex medical challenges. His legacy continues to influence the next generation of researchers and inventors in the pharmaceutical industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…